−23.65USD
−123.28 MUSD
2.45 MUSD
16.28 M
About Praxis Precision Medicines, Inc.
Sector
CEO
Marcio Souza
Headquarters
Boston
Website
Employees (FY)
82
Founded
2015
FIGI
BBG00W9LF2G5
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PRAX is 48.84 USD — it has increased by 2.22% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Praxis Precision Medicines, Inc. stocks are traded under the ticker PRAX.
Praxis Precision Medicines, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
PRAX stock is 5.52% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is Praxis Precision Medicines, Inc. there?
PRAX earnings for the last quarter are −2.70 USD per share, whereas the estimation was −3.90 USD resulting in a 30.77% surprise. The estimated earnings for the next quarter are −3.05 USD per share. See more details about Praxis Precision Medicines, Inc. earnings.
Yes, you can track Praxis Precision Medicines, Inc. financials in yearly and quarterly reports right on TradingView.
PRAX stock has fallen by 6.51% compared to the previous week, the month change is a 9.15% fall, over the last year Praxis Precision Medicines, Inc. has showed a 193.48% increase.
PRAX net income for the last quarter is −26.88 M USD, while the quarter before that showed −24.63 M USD of net income which accounts for −9.12% change. Track more Praxis Precision Medicines, Inc. financial stats to get the full picture.
Today Praxis Precision Medicines, Inc. has the market capitalization of 834.57 M, it has decreased by 8.83% over the last week.
No, PRAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PRAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Praxis Precision Medicines, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 82.00 employees. See our rating of the largest employees — is Praxis Precision Medicines, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Praxis Precision Medicines, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Praxis Precision Medicines, Inc. stock shows the neutral signal. See more of Praxis Precision Medicines, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Praxis Precision Medicines, Inc. future price: according to them, PRAX price has a max estimate of 270.00 USD and a min estimate of 40.00 USD. Read a more detailed Praxis Precision Medicines, Inc. forecast: see what analysts think of Praxis Precision Medicines, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Praxis Precision Medicines, Inc. EBITDA is −125.32 M USD, and current EBITDA margin is −5.15 K%. See more stats in Praxis Precision Medicines, Inc. financial statements.